The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan.

The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan. - The inhibitory effects of the SGLT2 inhibitor for progression of diabetic nephropathy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016754

Enrollment

Registered

2015-04-01

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy in type 2 diabetes mellitus

Interventions

oral administration of ipragliflozin (50mg/day) oral administration of ipragliflozin (50mg/day) oral administration of glimepiride (1-2mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Diet and exercise therapy only for one month or more, or in addition to diet and exercise therapy, in SGLT2 inhibitors other than oral hypoglycemic agents for one month or more, the glycemic control is insufficient (HbA1c 6.0% or more (NGSP)) 2)Patients who is obtained the consent in writing

Exclusion criteria

Exclusion criteria: 1)Patient with a severe ketotic diabetic coma or precoma. 2)Patient with severe infectious disease, before and after operation, and a serious injury. 3)End-stage renal failure patients with severe renal impairment (eGFR <30mL / min) or during dialysis 4)A pregnant woman or woman who may be pregnant. 5)Patient with a past history of hypersensitivity for Ipragliflozin. 6)Patients who isn't obtained the consent in writing 7)Patient who is considered to be inappropriate by the chief physician.

Design outcomes

Primary

Measure	Time frame
1)blood glucose lowering effect; fasting blood glucose, HbA1c, 1.5-AG, HOMA-beta, HOMA-R 2)renal function; eGFRcrest, eGFRcys, UACR 3)renal tubular function; u-Na, u-K, u-Cl, u-Mg, u-Ca, u-P, u-Zn, u-UA, u-HCO3, u-pH, FENa, FEK, FECl, FEMg, FECa, FEP, FEZn, FEUA, NAG, u-beta2MG, u-L-FABP, u-Col4	—

Secondary

Measure	Time frame
1)oxidant stress; hs-CRP, MDA-LDL, u-isoprostane, u-MCP-1 2)bone metabolic markers; FGF-23, whole PTH 3)lipid profile; LDL-C, HDL-C, TG 4)body fluid volume; NT-proBNP, renin, aldosterone 5)urine volume, urinary pH 6)bood pressure, heart rate, body weight, octopolar bioimpedance 7)RBC, Hb, Erythropoietin	—

Countries

Japan

Contacts

Public ContactSaeko Sato

Saitama Medical Center, Saitama Medical University Department of Nephrology and Hypertention

saeko_s@saitama-med.ac.jp049-228-3400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026